These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 21896911)

  • 1. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
    Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
    AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
    Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
    J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
    Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
    Mirochnick M; Taha T; Kreitchmann R; Nielsen-Saines K; Kumwenda N; Joao E; Pinto J; Santos B; Parsons T; Kearney B; Emel L; Herron C; Richardson P; Hudelson SE; Eshleman SH; George K; Fowler MG; Sato P; Mofenson L;
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):33-41. PubMed ID: 23979002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
    AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Chi BH; Chintu N; Cantrell RA; Kankasa C; Kruse G; Mbewe F; Sinkala M; Smith PJ; Stringer EM; Stringer JS
    J Acquir Immune Defic Syndr; 2008 Jun; 48(2):220-3. PubMed ID: 18520682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).
    Hirt D; Pruvost A; Ekouévi DK; Urien S; Arrivé E; Kone M; Nerrienet E; Nyati M; Gray G; Kruy LS; Blanche S; Dabis F; Tréluyer JM
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2953-60. PubMed ID: 21464241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
    JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
    Hirt D; Urien S; Rey E; Arrivé E; Ekouévi DK; Coffié P; Leang SK; Lalsab S; Avit D; Nerrienet E; McIntyre J; Blanche S; Dabis F; Tréluyer JM
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1067-73. PubMed ID: 19104016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.